Quantcast

Latest Non-Hodgkin lymphoma Stories

2012-03-08 08:00:00

Cancer Monthly, the only centralized source of cancer treatment results, adds two new cancers to the database. Raleigh, NC (PRWEB) March 08, 2012 Cancer Monthly is proud to announce that it now provides treatment results for Non Hodgkin´s Lymphoma and Bladder Cancer. Cancer Monthly is the only centralized source of cancer treatment results. Founded more than seven years ago, Cancer Monthly now provides information on the actual performance for nearly 1,000 different treatments for...

2011-12-21 22:50:49

Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method yet for imaging a form of Non-Hodgkin´s disease called mantle cell lymphoma, a relatively rare and devastating blood cancer. The pilot study is published in the December issue of The Journal of Nuclear Medicine. Lymphoma is the term used for an array of cancers that affect blood cells and the lymphatic system. These cancers are typically...

2011-08-19 16:10:00

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers - Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent...

2011-08-19 13:52:00

SILVER SPRING, Md., Aug. 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Lymphomas are cancers of the lymphatic system. Adcetris is an antibody-drug conjugate that combines an antibody and drug, allowing the antibody to direct the drug to a target on...

2011-07-25 11:52:09

(Ivanhoe Newswire) "“ Hodgkin's lymphoma is one of the most treatable cancers, with more than 90 percent of patients surviving after a combination of radiation and chemotherapy. New research has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment. Knowing in advance who is at risk could help physicians tailor treatment to reduce the risks for patients who are most...

2011-07-19 16:16:51

Study finds novel interaction between 2 proteins that regulate cell growth Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma. In a study published online in Nature Communications, the scientists report that they have found a complex molecular and functional...

2011-06-09 13:28:23

Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK. The team, from the University's Institute for Cancer Studies and funded by Leukaemia and Lymphoma Research, Biotechnology and Biological Sciences Research Council (BBSRC) and Yorkshire Cancer Research, found that a mechanism different to that previously thought to be the cause of lymphoma may be responsible for the development of the...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related